Ayuda
Ir al contenido

Dialnet


Resumen de Memantina, una nueva alternativa en el tratamiento de la enfermedad de Alzheimer

M. Calabuig Muñoz, Geronima Riera Sendra, Sònia Jornet Montaña, Laura Canadell Vilarrasa, María Vuelta Arce

  • Alzheimer's disease is a degenerative pathology of progressive character that affects the brain, by provoking a deterioration of memory, the intelligence and the behavior. This type of dementia originates a loss of the patient's cognitive functions that reverts, in the long run, with the impossibility of adaptation to social life. In the last few years, advances in the knowledge of this disease's pathogenesis have occurred and the type of therapy utilized is based on enhancing the delay of its beginning, slowing down its progress and improving on its symptomatology. The knowledge of Alzheimer's disease's physiopathology on the level of the N-methyl-D-aspartate (NMDA) receptor opens the doors to a new way of treatment: NMDA receptor inhibitors like the memantine. Memantine is used in moderately grave and grave states of the disease, with few side effects and with statistically significant improvements with respect to the placebo on a functional and cognitive level, reducing the dependence on other people care


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus